交易 Genprex, Inc. - GNPX CFD
加入收藏夹- 概括
- 历史数据
- 活动
- 收入报表
- 资产负债表
- 现金流
- 所有权
交易条件
| 价差 | 0.0321 | ||||||||
|
多头隔夜费
Long position overnight fee
前往平台 | -0.024068% | ||||||||
|
空头隔夜费
Short position overnight fee
前往平台 | 0.001846% | ||||||||
| 隔夜费时间 | 21:00 (UTC) | ||||||||
| 最小交易量 | 1 | ||||||||
| 货币 | USD | ||||||||
| 保证金 | 20% | ||||||||
| 上市交易所 | United States of America | ||||||||
| 交易费 | 0% |
*Information provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | 平倉 | Change | Change (%) | 開倉 | High | Low |
|---|---|---|---|---|---|---|
| Mar 22, 2023 | 0.7960 | -0.0021 | -0.26% | 0.7981 | 0.8149 | 0.7775 |
| Mar 21, 2023 | 0.7603 | 0.0151 | 2.03% | 0.7452 | 0.7772 | 0.7283 |
| Mar 20, 2023 | 0.7274 | -0.0656 | -8.27% | 0.7930 | 0.7931 | 0.7210 |
| Mar 17, 2023 | 0.7449 | -0.0700 | -8.59% | 0.8149 | 0.8149 | 0.7283 |
| Mar 16, 2023 | 0.7870 | -0.0179 | -2.22% | 0.8049 | 0.8091 | 0.7558 |
| Mar 15, 2023 | 0.7945 | -0.0751 | -8.64% | 0.8696 | 0.8781 | 0.7677 |
| Mar 14, 2023 | 0.8400 | -0.1078 | -11.37% | 0.9478 | 0.9541 | 0.8400 |
| Mar 13, 2023 | 0.8952 | 0.0272 | 3.13% | 0.8680 | 0.9172 | 0.8505 |
| Mar 10, 2023 | 0.8868 | -0.1109 | -11.12% | 0.9977 | 1.0077 | 0.8779 |
| Mar 9, 2023 | 0.9977 | -0.0299 | -2.91% | 1.0276 | 1.0376 | 0.9937 |
| Mar 8, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.0975 | 1.0077 |
| Mar 7, 2023 | 1.0276 | -0.0699 | -6.37% | 1.0975 | 1.1075 | 1.0176 |
| Mar 6, 2023 | 1.0875 | -0.0200 | -1.81% | 1.1075 | 1.1175 | 1.0875 |
| Mar 3, 2023 | 1.1175 | -0.0299 | -2.61% | 1.1474 | 1.1574 | 1.0875 |
| Mar 2, 2023 | 1.1274 | -0.0100 | -0.88% | 1.1374 | 1.1574 | 1.0576 |
| Mar 1, 2023 | 1.1274 | -0.1197 | -9.60% | 1.2471 | 1.2671 | 1.1174 |
| Feb 28, 2023 | 1.2671 | 0.1597 | 14.42% | 1.1074 | 1.3370 | 1.1074 |
| Feb 27, 2023 | 1.1174 | -0.1098 | -8.95% | 1.2272 | 1.2272 | 1.0975 |
| Feb 24, 2023 | 1.3170 | 0.0000 | 0.00% | 1.3170 | 1.3769 | 1.2970 |
| Feb 23, 2023 | 1.3669 | -0.3992 | -22.60% | 1.7661 | 1.8659 | 1.2871 |
Genprex, Inc. Events
| 時間（協調世界時） (UTC) | 國家 | 事件 |
|---|---|---|
| No events scheduled | ||
- 年度
- 每季度
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| 总收入 | 0 | 0 | 0 | 0 | 0 |
| 收入 | 0 | 0 | 0 | 0 | 0 |
| 总营业费用 | 19.6008 | 17.9616 | 10.6827 | 12.3635 | 3.31235 |
| 销售/一般/行政费用，总计 | 10.9705 | 10.6359 | 8.7026 | 11.3862 | 3.01917 |
| 研究与开发 | 8.60775 | 7.30292 | 1.96701 | 0.97143 | 0.28993 |
| Depreciation / Amortization | 0.02253 | 0.02278 | 0.01307 | 0.00589 | 0.00324 |
| 营业收入 | -19.6008 | -17.9616 | -10.6827 | -12.3635 | -3.31235 |
| 税前净收入 | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 税后净收入 | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 未计算非常项目前的净收益 | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 净收入 | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 普通股股东可获收益 (不含非经常性项目) | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 普通股股东可获收益 (含非經常性項目) | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 摊薄调整 | |||||
| 摊薄净收入 | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 摊薄后加权平均股 | 47.0973 | 35.5229 | 16.027 | 13.771 | 13.035 |
| 扣除特别项目的每股摊薄盈利 | -0.41607 | -0.5051 | -0.6648 | -0.89843 | -0.25425 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| 每股正常摊薄盈利 | -0.41607 | -0.5051 | -0.6648 | -0.89843 | -0.25425 |
| 利息收入（费用），非经营净值 | 0.00513 | 0.01881 | 0.02791 | -0.0088 | -0.00181 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| 总收入 | 0 | 0 | 0 | 0 | 0 |
| 收入 | 0 | 0 | 0 | 0 | 0 |
| 总营业费用 | 5.72336 | 5.68292 | 3.43893 | 3.98722 | 6.4917 |
| 销售/一般/行政费用，总计 | 3.8558 | 2.19563 | 2.00044 | 2.4581 | 4.31631 |
| 研究与开发 | 1.86084 | 3.48033 | 1.432 | 1.52628 | 2.16914 |
| Depreciation / Amortization | 0.00673 | 0.00696 | 0.00649 | 0.00285 | 0.00624 |
| 营业收入 | -5.72336 | -5.68292 | -3.43893 | -3.98722 | -6.4917 |
| 利息收入（费用），非经营净值 | 0.00088 | 0.00099 | 0.00106 | 0.0011 | 0.00198 |
| 税前净收入 | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 税后净收入 | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 未计算非常项目前的净收益 | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 净收入 | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 普通股股东可获收益 (不含非经常性项目) | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 普通股股东可获收益 (含非經常性項目) | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 摊薄净收入 | -5.72248 | -5.68193 | -3.43787 | -3.98612 | -6.48971 |
| 摊薄后加权平均股 | 47.8796 | 47.8353 | 47.6124 | 47.3725 | 45.5461 |
| 扣除特别项目的每股摊薄盈利 | -0.11952 | -0.11878 | -0.07221 | -0.08414 | -0.14249 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| 每股正常摊薄盈利 | -0.11952 | -0.11878 | -0.07221 | -0.08414 | -0.14249 |
- 年度
- 每季度
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| 流动资产总额 | 39.1402 | 27.7044 | 2.97664 | 8.84707 | 0.19357 |
| 现金和短期投资 | 38.6289 | 27.3197 | 2.00249 | 8.60092 | 0.16125 |
| Cash | 38.6289 | 27.3197 | 2.00249 | 8.60092 | 0.16125 |
| Prepaid Expenses | 0.51135 | 0.38455 | 0.17172 | 0.23685 | 0.02348 |
| Total Assets | 42.8623 | 31.3672 | 3.53423 | 9.26896 | 1.25954 |
| Property/Plant/Equipment, Total - Net | 0.04861 | 0.03944 | 0.04465 | 0.02435 | 0.0078 |
| Intangibles, Net | 3.66476 | 3.61267 | 0.4912 | 0.37945 | 0.29857 |
| Other Long Term Assets, Total | 0.00869 | 0.01074 | 0.02173 | 0.01809 | 0.75959 |
| Total Current Liabilities | 1.5853 | 0.45072 | 0.51068 | 0.38782 | 0.83096 |
| Accounts Payable | 0.9732 | 0.19297 | 0.43626 | 0.29507 | 0.62907 |
| Notes Payable/Short Term Debt | 0 | 0 | 0.07443 | 0.09275 | 0.20189 |
| Total Liabilities | 1.5853 | 0.45072 | 0.51068 | 0.38782 | 0.83096 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 41.277 | 30.9165 | 3.02355 | 8.88114 | 0.42857 |
| Preferred Stock - Non Redeemable, Net | |||||
| Common Stock | 0.04787 | 0.04312 | 0.01926 | 0.01524 | 0.01172 |
| Additional Paid-In Capital | 119.247 | 89.2956 | 43.4837 | 38.6906 | 17.8692 |
| Retained Earnings (Accumulated Deficit) | -78.0179 | -58.4222 | -40.4795 | -29.8247 | -17.4524 |
| Total Liabilities & Shareholders’ Equity | 42.8623 | 31.3672 | 3.53423 | 9.26896 | 1.25954 |
| Total Common Shares Outstanding | 47.8747 | 43.1177 | 19.2638 | 15.2392 | 13.035 |
| 应收账款总额，净额 | 0 | 0.00013 | 0.00066 | 0.0093 | 0.00884 |
| Accounts Receivable - Trade, Net | 0 | 0.00013 | 0.00066 | 0.0093 | 0.00884 |
| Total Inventory | 0.80178 | ||||
| Other Current Liabilities, Total | 0.6121 | 0.25776 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| 流动资产总额 | 35.7031 | 39.1402 | 45.6447 | 48.0615 | 50.3777 |
| 现金和短期投资 | 34.5553 | 38.6289 | 42.0205 | 44.2435 | 47.0687 |
| Cash | 34.5553 | 38.6289 | 42.0205 | 44.2435 | 47.0687 |
| 应收账款总额，净额 | 0.03217 | 0 | 0.00013 | 0.00013 | 0.00013 |
| Accounts Receivable - Trade, Net | 0.03217 | 0 | 0.00013 | 0.00013 | 0.00013 |
| Total Inventory | 2.87505 | 3.06236 | 3.1079 | ||
| Prepaid Expenses | 1.1156 | 0.51135 | 0.74903 | 0.7556 | 0.201 |
| Total Assets | 39.4094 | 42.8623 | 46.3272 | 48.7314 | 51.0365 |
| Property/Plant/Equipment, Total - Net | 0.04188 | 0.04861 | 0.04434 | 0.03949 | 0.0373 |
| Intangibles, Net | 3.65444 | 3.66476 | 0.62736 | 0.61967 | 0.6107 |
| Other Long Term Assets, Total | 0.01 | 0.00869 | 0.01074 | 0.01074 | 0.01074 |
| Total Current Liabilities | 2.38482 | 1.5853 | 1.16189 | 1.04722 | 0.61363 |
| Accounts Payable | 1.25298 | 0.9732 | 0.59194 | 0.36979 | 0.33897 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 1.13184 | 0.6121 | 0.56995 | 0.67743 | 0.27466 |
| Total Liabilities | 2.38482 | 1.5853 | 1.16189 | 1.04722 | 0.61363 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 37.0246 | 41.277 | 45.1653 | 47.6842 | 50.4229 |
| Common Stock | 0.04788 | 0.04787 | 0.0478 | 0.04752 | 0.04732 |
| Additional Paid-In Capital | 120.717 | 119.247 | 117.453 | 116.535 | 115.287 |
| Retained Earnings (Accumulated Deficit) | -83.7403 | -78.0179 | -72.3359 | -68.8981 | -64.9119 |
| Total Liabilities & Shareholders’ Equity | 39.4094 | 42.8623 | 46.3272 | 48.7314 | 51.0365 |
| Total Common Shares Outstanding | 47.8797 | 47.8747 | 47.8036 | 47.5229 | 47.3148 |
| Other Equity, Total | 0 |
- 年度
- 每季度
| 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|
| 净收入/起跑线 | -19.5956 | -17.9428 | -10.6548 | -12.3723 | -3.31416 |
| 经营活动产生的现金 | -14.2849 | -13.9351 | -6.91872 | -6.84653 | -2.17159 |
| 经营活动产生的现金 | 0.02253 | 0.02278 | 0.01307 | 0.00589 | 0.00324 |
| 非现金物品 | 4.27821 | 4.24619 | 3.52998 | 5.43538 | 1.32389 |
| 营运资金的变化 | 1.00995 | -0.26128 | 0.19299 | 0.08454 | -0.18457 |
| 投资活动产生的现金 | -0.0838 | -2.33725 | -0.9469 | -0.10332 | -0.06342 |
| 资本支出 | -0.07244 | -0.12799 | -0.14512 | -0.10332 | -0.06342 |
| 融资活动产生的现金 | 25.6779 | 41.5895 | 1.26719 | 15.3895 | 0.79397 |
| 股票的发行（报废），净额 | 25.6779 | 41.5895 | 1.26719 | 15.3895 | 0.79397 |
| 现金净变化 | 11.3092 | 25.3172 | -6.59843 | 8.43967 | -1.44104 |
| 其他投资现金流量项目，总计 | -0.01136 | -2.20926 | -0.80178 |
| Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -5.72248 | -19.5956 | -13.9137 | -10.4758 | -6.48971 |
| Cash From Operating Activities | -4.08386 | -14.2849 | -11.0668 | -8.43209 | -5.46528 |
| Cash From Operating Activities | 0.00673 | 0.02253 | 0.01558 | 0.00909 | 0.00624 |
| Non-Cash Items | 1.47011 | 4.27821 | 2.48457 | 1.8092 | 0.67174 |
| Cash Taxes Paid | 0 | 0 | |||
| Cash Interest Paid | 0 | 0 | |||
| Changes in Working Capital | 0.16179 | 1.00995 | 0.34669 | 0.22545 | 0.34645 |
| Cash From Investing Activities | 0.01032 | -0.0838 | 0.08978 | -0.07851 | -0.11003 |
| Capital Expenditures | -0.00184 | -0.07244 | -0.04622 | -0.02719 | -0.10077 |
| Other Investing Cash Flow Items, Total | 0.01216 | -0.01136 | 0.136 | -0.05132 | -0.00926 |
| Cash From Financing Activities | 0 | 25.6779 | 25.6779 | 25.4344 | 25.3243 |
| Issuance (Retirement) of Stock, Net | 0 | 25.6779 | 25.6779 | 25.4344 | 25.3243 |
| Net Change in Cash | -4.07354 | 11.3092 | 14.7008 | 16.9238 | 19.749 |
| 投资者名称 | 投资者类型 | 流通股百分比 | 持有股份 | 股份变动 | 持有日期 | 换手率 |
|---|---|---|---|---|---|---|
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.5144 | 1826600 | 1043 | 2022-12-31 | LOW |
| Varner (John Rodney) | Individual Investor | 2.2348 | 1161535 | 625000 | 2023-02-18 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.069 | 555623 | 2408 | 2022-12-31 | LOW |
| Confer (Ryan M.) | Individual Investor | 0.8379 | 435499 | 245000 | 2023-02-18 | MED |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.8314 | 432137 | -8520 | 2022-12-31 | LOW |
| Berger (Mark Stanley) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
| Vaczy (Catherine M) | Individual Investor | 0.4714 | 245000 | 245000 | 2023-02-18 | |
| Kumar (Hermant) | Individual Investor | 0.3848 | 200000 | 200000 | 2023-02-18 | |
| UBS Financial Services, Inc. | Investment Advisor | 0.3089 | 160546 | -119788 | 2022-12-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.2496 | 129739 | 0 | 2022-12-31 | LOW |
| Cypress Capital, LLC | Investment Advisor | 0.1924 | 100000 | 0 | 2022-12-31 | MED |
| Verus Capital Partners, LLC | Investment Advisor | 0.1703 | 88500 | -2000 | 2022-12-31 | MED |
| Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1663 | 86430 | 11029 | 2022-12-31 | LOW |
| Group One Trading, L.P. | Research Firm | 0.1161 | 60354 | -79668 | 2022-12-31 | HIGH |
| Silvercrest Asset Management Group LLC | Investment Advisor/Hedge Fund | 0.1077 | 56000 | 0 | 2022-12-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 0.1056 | 54900 | -18656 | 2022-12-31 | HIGH |
| IHT Wealth Management, LLC | Investment Advisor | 0.1008 | 52375 | 0 | 2022-12-31 | LOW |
| Staley Capital Advisers, Inc. | Hedge Fund | 0.0962 | 50000 | 0 | 2022-12-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 0.0687 | 35688 | 21508 | 2022-12-31 | HIGH |
| StoneX Group Inc. | Research Firm | 0.0676 | 35150 | 0 | 2022-12-31 | HIGH |
交易計算器
如果您在特定日期（选择一个日期）开立差价合约交易并在不同日期（选择一个日期）关闭交易，计算您的假设盈亏。
貿易佣金
0
- 1:1
杠杆
1:1
- 20
- 100
- 500
- 1000
- 10000
投資
交易規模（槓桿 x 投資）：
開倉
平倉
做空 做多
Genprex, Inc. Company profile
关于 Genprex Inc.
Genprex公司是一家临床阶段的基因治疗公司，致力于开发癌症和糖尿病的治疗方法。 公司的主要癌症候选药物REQORSA免疫基因治疗药物（也被称为GPX-001）正在开发中，用于治疗非小细胞肺癌（NSCLC）。 REQORSA的活性剂是一种TUSC2基因表达质粒，被封装在DOTAP胆固醇纳米粒子中。 TUSC2是一种肿瘤抑制基因，具有杀伤肿瘤（通过细胞凋亡）和免疫调节作用。 公司利用其ONCOPREX纳米粒子输送系统将表达TUSC2基因的质粒输送到癌细胞。 其糖尿病基因疗法，也被称为GPX-002，旨在通过将胰腺中的α细胞转化为功能性的β样细胞来发挥作用，这种细胞可以产生胰岛素，但与β细胞有足够的区别，可以躲避人体的免疫系统。
| Industry: | Bio Therapeutic Drugs |
Suite 3.322
1601 Trinity Street, Bldg. B
78712
收入报表
- Annual
- Quarterly
人们也观看
还在找一位您可以信任的经纪商吗？
加入成为全球500,000万多名交易者的一份子，选择利用Capital.com进行交易吧。